Inhibition of gastric inhibitory polypeptide signaling prevents obesity
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance. In contrast, mice lacking the GIP receptor (Gipr(-/-)) fed a high-fat diet were clearly protected from both the obesity and the insulin resistance. Moreover, double-homozygous mice (Gipr(-/-), Lep(ob)/Lep(ob)) generated by crossbreeding Gipr(-/-) and obese ob/ob (Lep(ob)/Lep(ob)) mice gained less weight and had lower adiposity than Lep(ob)/Lep(ob) mice. The Gipr(-/-) mice had a lower respiratory quotient and used fat as the preferred energy substrate, and were thus resistant to obesity. Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“tirzepatide proved superior in improving glycemic control relative to treatment with semaglutide (1 mg)133, insulin degludec134, insulin glargine135,136, and insulin lispro137; importantly, with preserved efficacy and without compromising safety in subjects at risk for cardiovascular diseases136.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [136]
In the citing paper
“While GIPR antagonism has been shown to reduce adiposity in preclinical models [64], the clinical data show tirzepatide, a dual GLP-1R/GIPR agonist, produces greater weight loss and glucose lowering than the GLP-1R agonist semaglutide alone [42], particularly at doses which comparably engage the GLP-1R [61].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
In the citing paper
“Initial reports that GIPR null mice [64] are protected from diet-induced obesity have been supported by preclinical studies in rodents and non-human primates that GIPR antagonism induces additive weight loss when combined with GLP-1R agonism [32,67], and human genetics data that loss-of-function GIPR variants associate with reduced adiposity [68].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [64]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419 · cited 1×
“Obese Lep ob / Lep ob mice exhibit a marked increase in adipose tissue due to hyperphagia caused by mutation of the leptin gen”
BackgroundSerum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science · doi:10.1126/science.7624777 · Cited by 4,451
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Obesity and the regulation of energy balance
Spiegelman, B. M., & Flier, J. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00240-9 · Cited by 2,398
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Green, H., & Kehinde, O. (1975) · Cell · doi:10.1016/0092-8674(75)90087-2 · Cited by 1,360
Dietary fat intake does affect obesity!
Bray, G. A., & Popkin, B. M. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.6.1157 · Cited by 1,123
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Cited by
Items 901–972 of 972
Descifrando las funciones de la microbiota intestinal en la obesidad.
López‐Almela, I. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/174897
The Role of Incretins in Insulin Secretion
Salehi, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_4
Regional Intestinal Drug Absorption
Gonzalez-Alvarez, M. I., & Dahan, A. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-3657-6
4. Entero-pancreatic Endocrine Function and Diabetes
Inagaki, N. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.1713
Goran, M. I. (2016) · CRC Press eBooks · doi:10.1201/9781315370958-14
Secretion and Impact of Gut Hormones in Obesity and Diabetes
Holst, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00264-9
Self-citationSachs, S., Götz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2023) · Research Square · doi:10.21203/rs.3.rs-2912233/v1
Beslenmenin Merkezi ve Periferal Regülasyonu
KESKİN, E., & GEZGİÇ, B. (2023) · doi:10.59287/sbyc.543
Veränderungen der Sekretion und biologischen Wirksamkeit von Inkretinhormonen bei Typ-2-Diabetes
Quast, D. R., & Nauck, M. A. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01146-w
“Ursprünglich sprach die Be-obachtung,dassMäusemit Knock-out des GIP-Rezeptors unter fettreicher Diät weniger zunehmen als Wildtyptiere [24], für eine entscheidende Rolle des GIP-Rezep-tors bei der Genese der Gewichtszunah-me.”
Régulation et fonctions du facteur de transcription ChREBP dans l'épithélium intestinal
Charifi, W. (2021) · theses.fr (ABES) · doi:10.70675/89543c3fz31abz4d56zaa7bz77c2c07ffd69
Adaptive responses of the ileum of NOD mice to low‐dose fluoride: A proteomic exploratory study
Trevizol, J. S., Buzalaf, N. R., Dionizio, A. S., Delgado, A. Q., de Lara, J. P. Z., Magalhães, A. C., Bosqueiro, J. R., & Buzalaf, M. A. R. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3976
“23 In this study, nonobese ‐ diabetic (NOD) mice, a validated model for evaluating agents and protocols that prevent or reverse type 1 diabetes, 24 were used to assess the proteomic changes induced by low doses of F in the ileum.”
BackgroundAupetit, A. (2023) · theses.fr (ABES) · doi:10.70675/11dfa53dzf238z4a69zb5e6z7c2f7a6fe56e
4) Update of GLP-1 Receptor Agonists
Inagaki, N. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.1613
Davies, I., Manchanda, Y., Sloop, K. W., Bloom, S. R., Tan, T., Tomás, A., & Jones, B. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16216
New biomarkers of nutritional status
Bronský, J., & Průša, R. (2008) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2008.003 · Cited by 1
Yamamoto, Y., Kobayashi, M., Togawa, T., Sekine, O., Ozamoto, Y., Fuse, J., Ito‐Kobayashi, J., Oe, Y., Hagiwara, A., Iwanishi, M., et al. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2024
Manchanda, Y., Desoki, R., Gardner, E. J., Perry, J. R. B., Wainscott, D. B., Stutsman, C., Langenberg, C., Coghlan, M. P., Bhatnagar, P., Ho, J. D., et al. (2025) · medRxiv · doi:10.1101/2025.08.15.25333807
Varra, F., Varras, M. N., Varra, V., & Theodosis‐Nobelos, P. (2025) · Current Clinical Pharmacology · doi:10.2174/0127724328392698250818071803 · Cited by 3
Contrasting roles for GLP-1R and GIPR in a model of diet-induced obesity
Gao, J., Cree, S., Ham, S., Nowell, C. J., Parker, A., Zhao, P., Whiting, L., Sloop, K. W., Samms, R. J., Sexton, P. M., et al. (2025) · Journal of Molecular Endocrinology · doi:10.1530/jme-25-0053
Editorial: The impact of GIP/GIPR on metabolic diseases: how the field is evolving
Habegger, K. M., Tomás, A., Chen, R., Harris, C., Roell, W. C., & Coşkun, T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1710843
EndoCompass Project: Research Roadmap for Diabetes, Obesity, and Metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000549194 · Cited by 1
“Both agonists and antagonists of the GIP receptor have been shown to prevent obesity, as evidenced by studies demonstrating that GIP receptor antagonism can reduce weight gain in mice [134].”
Gastrointestinale Hormonsysteme und ihre Regulation
Göke, B., de Heer, J., & Göke, R. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_11
Hanson, A. A. (2022) · uO Research (University of Ottawa) · doi:10.20381/ruor-27367
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26633796
Sachs, S., Goetz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26611103
Sachs, S., Goetz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26611100
Boutari, C., Stefanakis, K., Simati, S., Guatibonza-García, V., Valenzuela‐Vallejo, L., Anastasiou, I. A., Connelly, M. A., Kokkinos, A., & Mantzoros, C. S. (2024) · Figshare · doi:10.6084/m9.figshare.26722629
Sachs, S., Goetz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26611097
Gastro-intestinal hormones and their regulation of food intake
Busetto, L., Shojaei, F. S., Rossato, M., & Vettor, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00332-0
Isidora, S., Parada, J., Cataldo, L. R., Galgani, J. E., Alberti, G., Labayen, I., & Santos, J. L. (2025) · Endocrine Connections · doi:10.1530/ec-25-0804
“Interestingly, loss-of-function mutations in the GIP receptor (GIPR) in humans and Gipr knockout mice have been linked to resistance to obesity and improved insulin sensitivity (19, 20, 21, 22).”
Furtado, M. C. M. B. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., & Dovč, K. (2026) · DiRROS repository (University of Maribor)
The Effects of Small Intestinal Protein Sensing on Glucose Homeostasis
Barros, D. (2023) · TSpace (University of Toronto)
Rodríguez, Y. C. U. (2020) · Repositorio Universidad Distrital
Andrews, K. E., Sibthorpe, P. E. M., Fitzgerald, D. M., & de Laat, M. A. (2026) · The Veterinary Journal · doi:10.1016/j.tvjl.2026.106644
Piccand, J. (2012) · theses.fr (ABES) · doi:10.70675/9f80f37azfaacz4e60z8cd8zd178cf6a58ac
“Gipr‐ null mice have less fat, use fat as preferred energy, are resistant to diet‐induced obesity and have improved insulin sensitivity (Miyawaki et al., 2002).”
Adaptation postprandiale du métabolisme intestinal des lipides : rôle du CD36 et du PPAR béta
Tran, T. T. T. (2011) · theses.fr (ABES) · doi:10.70675/d0362285zd283z4114z89afz757b71665cc1 · Cited by 1
Adaptive changes of human islets to an obesogenic environment in the mouse
Gargani, S. (2013) · theses.fr (ABES) · doi:10.70675/cebf7176z1bb8z414bzb159ze850f327d2d5
“On the other hand, HFD mice seem to have higher levels of GIP and GIPKO mice are protected from obesity and insulin resistance [96, 97].”
Duraffourd, C. C. (2010) · theses.fr (ABES) · doi:10.70675/c5de2109zfa59z402bz9f3fz60efa3da23b0
Vadder, F. D. (2014) · theses.fr (ABES) · doi:10.70675/9ffe2312z229az4d65za513zd70667e79a8a · Cited by 1
Gastrointestinal plasticity in health and diseases : what we have learned from bariatric surgeries
Cavin, J. (2016) · theses.fr (ABES) · doi:10.70675/29903f51zf03bz4eb4z9e92z679412d484ee
Hormones intestinales et remodelage osseux
Gobron, B. (2020) · theses.fr (ABES) · doi:10.70675/dce7301cz8d6ez4effz9eebz1548099e70f7
Role du neuropeptide 26RFa dans le controle de l'homéostasie glucidique par l'hypothlamus.
Mehdi, M. E. (2020) · theses.fr (ABES) · doi:10.70675/8b714030z33a9z4b08za1daz2e69dea9767b
Α-gustducine intestinale : implication dans l'obésité et le diabète de type 2
Gléau, L. L. (2021) · theses.fr (ABES) · doi:10.70675/dc436e75zb6d2z4bb4zb9a1z17b025f205a6
Effets de la chirurgie bariatrique préconceptionnelle sur le métabolisme osseux
Couchot, M. (2024) · theses.fr (ABES) · doi:10.70675/528e8f84zff5cz4fe1z9455z6038d994cf0e
Long, Y., Xu, Z., Zhang, N., Chen, G., Chen, W., Chen, Z., Wang, A., Liang, Z., Wang, Y., Zeng, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.21.719783
Regulators of appetite in mammals—old and new players
Fernandes, J. H., Silva, J. D., Costa, M. D., & Maciel, P. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag020 · Cited by 1
Vignera, S. L., Fioriglio, C., & Condorelli, R. A. (2026) · Diagnostics · doi:10.3390/diagnostics16131979
“Studies in rodent models of obesity have shown that GIP receptor knockout mice are resistant to diet-induced obesity and that GIP receptor antagonism can promote weight loss, leading to initial scepticism about the rationale for GIP receptor agonism in obesity treatment [57].”
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways
Lindquist, P., Dijkhof, L. R. H., Drzazga, A. K., Sabatier, P., Stępniewski, T. M., Granlund, L., Lechner, M. Y., Zhong, Y., Gasbjerg, L. S., Hartmann, B., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.06.003
Self-citationSun, Y., Xie, C., Huang, W., Bound, M. J., Grivell, J., Jones, K. L., Horowitz, M., Macdonald, I. A., Rayner, C. K., & Wu, T. (2026) · Diabetes · doi:10.2337/db26-0267
Selective Targeting Through Chemical Remodeling of Protein NeosurfacesPreprint
Wang, W., Wei, Q., Han, K., Wang, X., Zhang, J., Zhao, J., Zhang, X., Li, J., Zhang, W., Miao, X., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9212957/v1
Li, Y., Ye, D., Fu, C., Huang, X., Ma, Q., Zhang, F., Chen, G., Song, P., Kong, C., Wu, J., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2687937
“31,32 Our data support a context-dependent model of GIP action.”
Reitz, J., Rosoff, D. B., Pacher, P., & Lohoff, F. W. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100793 · Cited by 1
“GIPR/GLP1R Dual Agonist Therapeutics in Metabolic ALD Biological Psychiatry: Global Open Science November 2026; 6:100793 www.sobp.org/GOS weight (42,43).”
Agonists and Antagonists of the Human GIP Receptor
Kizilkaya, H. S., Gasbjerg, L. S., Holst, J. J., & Rosenkilde, M. M. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch2
Self-citationHe, W., Yi-di, S., Wang, X., He, S.-Y., Tao, X., Yuan, S.-X., Zhou, L., & Long, E.-W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1889594
“Its ability to promote lipid uptake and storage within adipose tissue once led to the view that the GIPR was not a suitable therapeutic target for obesity treatment (Marks, 2019; McClean et al., 2007; Miyawaki et al., 2002; Jones et al., 1989).”
Jin, C. A., Many, G. M., Spurrier, C. S. R., Borsellino, P., Wheeler, M. T., Adkins, J., Snyder, M. P., Newgard, C. B., Radom‐Aizik, S., Cooper, D. M., et al. (2026) · Physiological Genomics · doi:10.1152/physiolgenomics.00171.2026
Manchanda, Y., Desoki, R., Gardner, E. J., Perry, J. R. B., Wainscott, D. B., Stutsman, C., Langenberg, C., Coghlan, M. P., Bhatnagar, P., Ho, J. D., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec3372
“An early pivotal study demonstrated that Gipr knockout mice are resistant to weight gain when fed a high-fat diet ( 10 ), positioning GIPR antagonism as a potential therapeutic approach for weight loss.”
Martino, S. D., & Rosa, M. D. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930768
“Multiple genetic studies performed in humans demonstrated that lower GIPR expression or function is linked to decreased body mass index (Okada et al., 2012; Miyawaki et al., 2002).”
G-protein-coupled receptors (GPCRs) in the treatment of diabetes
Abirami, P. M., & Ramkumar, K. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33887-8.00018-0
Kim, K.-S., Lim, S., & Park, C.-Y. (2026) · EXCLI journal · doi:10.17179/excli2026-9310
Voller, B., Woodward, R. M., Murrin, O., Delgado, J., Türkmen, D., Hopkins, R., Violán, C., Mancini, M., Farmer, L., Boddy, K., et al. (2026) · medRxiv · doi:10.64898/2026.09.28.26364012
Liu, C., Wang, Y., Liu, J., Tian, P., Liu, J., Li, M., Zhang, Z., & Zhang, P. (2026) · Peptides · doi:10.1016/j.peptides.2026.171524
Yoshikawa, H., 이은영, Hatano, R., Taki, Y., Takaya, A., Eguchi, A., Goto, Y., Miyamoto, J., Kimura, I., Tanaka, T., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117889
Dieescting the effects of sweet tastants in the human gut-brain axis
Bryant, C. E. (2014) · Research Explorer (The University of Manchester) · Cited by 1
Metadata
- Authors
- Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., Hiai, H., Mizunoya, W., Fushiki, T., Holst, J. J., Makino, M., Tashita, A., Kobara, Y., Tsubamoto, Y., Jinnouchi, T., Jomori, T., & Seino, Y.
- Affiliations
- Kyoto University (JP)
- University of Copenhagen (DK)
- Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) (JP)
- Corresponding author
- Seino, Yutaka
- Venue
- Nature Medicine
- Published
- 2002-06-17
- Volume
- 8
- Issue
- 7
- Pages
- 738-742
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2102392334
- Cited by
- 963
- References
- 24
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 64 · 2023: 45 · 2022: 38 · 2021: 39 · 2020: 37 · 2019: 66 · 2018: 39 · 2017: 45 · 2016: 38 · 2015: 42 · 2014: 44 · 2013: 38 · 2012: 38
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, obesity, insulin resistance, high-fat diet, adiposity, respiratory quotient, fat oxidation, anti-obesity drugs, overnutrition
- MeSH terms
- Adipose Tissue, Animals, Body Weight, Crosses, Genetic, Dietary Fats, Gastric Inhibitory Polypeptide, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.